Skip to main content
Equibles
IPSC logo

IPSC · Century Therapeutics, Inc.

Track IPSC — free

Use IPSC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IPSC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.94 +0.00 (+0.00%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$351.29M
Shares
181.08M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.94 Open$1.98 Day$1.89–2.00 52W close$0.47–2.94 Avg vol 30d461K Short int29.5M · 16.3% float · 70.6d Short vol73% Last earningsMar 19, 2025 DataJun 2021–Sep 2026 Filing10-Q · Aug 12

Up next

Latest filing: 10-Q
filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$114.90M
Trailing 12 months
Net income (TTM)
−$109.79M
Trailing 12 months
Revenue growth YoY
+12,667.7%
Year over year
Operating margin
-15.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+138.6%
Year over year · more shares
Price change (1Y)
+281.9%
Trailing year
Short interest
16.3%
Latest settlement · 70.6 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −2%
below
Price vs 50-day avg −8%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 60%
mid-range
Momentum
relative strength
Weak
1-month return +1%
trailing
6-month return −20%
trailing
YTD return +95%
this year
Relative strength −38%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Accumulating
+35% holders QoQ · +36 funds added
Insider flow Distributing
Net -$2.2K over 90 days · 100% sells
Short interest Rising
16.31% of float · ▲ +0.5% MoM · 70.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
100 holders — near 3-yr high, broad support
Squeeze score 74
high risk · 0–100
Fundamentals
Strong
Revenue growth +1557%
Y/Y
EPS growth +91%
Y/Y
Free cash flow $-104.7M
Balance sheet $74.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 98%
annualized · 1-yr
Max drawdown −37%
past year
ATR 5.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−2% Neutral
Price vs 50-day avg
−8% Bearish
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
60% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Accumulating
+35% holders QoQ · +36 funds added
Insider flow Distributing
Net -$2.2K over 90 days · 100% sells
Short interest Rising
16.31% of float · ▲ +0.5% MoM · 70.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
100 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $0 Now $2 · 60% Range high $3
vs 200-day avg -2% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IPSC
Century Therapeutics, Inc.
this stock
$351.29M +95.0% +1556.8% — 16.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.40B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
100
% held
87.4%
Net QoQ
+19.5M sh
Top holder
TCG Crossover Management,…
Held Float
View
Held by Funds
Fund positions
62
View
Short & Settlement
Short Interest Rising
Shares short
29.5M
Days to cover
70.6d
Change
+158.8K sh
View
Short Volume
Short vol %
73%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
21.4K
Value
$41.2K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
41.1%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$2.2K
Buyers / Sellers
0 / 2
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$109.2M
Net income (FY)
$-9.6M
EPS diluted
$-0.14
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 9, 2026
This year
15
View
Proposed Sales
Value
$1.1K
Shares
534
Filed
Sep 8, 2026
View
Exempt Offerings
Offering
$160.0M
Filed
Mar 15, 2021
View
Earnings & Events
Earnings Calls
Last call
Mar 19, 2025
View
Investor Relations
Latest news
Century Therapeutics Appoints Jos…
Published
Sep 9, 2026
View

Performance

5D 20D 120D MTD YTD
IPSC -7.2% +0.5% -19.8% -5.4% +95.0%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -6.0% +2.3% -37.7% -5.0% +82.9%
Key facts CIK 1850119 CUSIP 15673T100 13F (30d) 59 filings 59 filers Visit website Investor relations